Changes in rat brain energetic metabolism after exposure to anandamide or Δ9-tetrahydrocannabinol

被引:35
作者
Costa, B [1 ]
Colleoni, M [1 ]
机构
[1] Univ Milan, Dept Pharmacol Chemotherapy & Med Toxicol, I-20129 Milan, Italy
关键词
cannabinoid; behavioural tolerance; brain; energetic metabolism; cannabinoid CB1 receptor-specific antagonist;
D O I
10.1016/S0014-2999(00)00170-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to investigate whether single and repeated administration of the cannabinoids anandamide or Delta(9)-tetrahydrocannabinol affected brain energetic metabolism. Single administration of either anandamide (20 mg/kg) or Delta(9)-tetrahydrocannabinol (10 mg/kg) in rats induced a behaviour typical with cannabinoids. An increase in both brain mitochondria oxidative phosphorylation and cerebral lipoperoxidation was shown ex vivo. The cannabinoid CB1 receptor-specific antagonist, N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR141716A; 3 mg/kg), reversed the anandamide-induced metabolic effects. Prolonged exposure to anandamide (20 mg/kg, 16 days) induced behavioural tolerance and the disappearance of the increased mitochondria oxygen uptake and lipoperoxidation. Repeated Delta(9)-tetrahydrocannabinol injection (10 mg/kg, twice daily, 4.5 days) reduced brain metabolism and uncoupled respiration from oxidative phosphorylation. The present findings showed that both anandamide and Delta(9)-tetrahydrocannabinol enhanced the energetic brain metabolism, probably via the cannabinoid CB1 receptor; the anandamide-tolerant brain of rats showed tolerance to the drug for metabolic effects, while the brain of Delta(9)-tetrahydrocannabinol-tolerant rats showed metabolic signs of neuronal damage, i.e. low energy production. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 39 条
[1]   NEUROBIOLOGY OF MARIJUANA ABUSE [J].
ABOOD, ME ;
MARTIN, BR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (05) :201-206
[2]   DEVELOPMENT OF BEHAVIORAL TOLERANCE TO DELTA-9-THC WITHOUT ALTERATION OF CANNABINOID RECEPTOR-BINDING OR MESSENGER-RNA LEVELS IN WHOLE-BRAIN [J].
ABOOD, ME ;
SAUSS, C ;
FAN, F ;
TILTON, CL ;
MARTIN, BR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 46 (03) :575-579
[3]   Nonclassical and endogenous cannabinoids: Effects on the ordering of brain membranes [J].
Bloom, AS ;
Edgemond, WS ;
Moldvan, JC .
NEUROCHEMICAL RESEARCH, 1997, 22 (05) :563-568
[4]  
CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65
[5]  
COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218
[6]   Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat [J].
Costa, B ;
Parolaro, D ;
Colleoni, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 313 (1-2) :17-24
[7]   SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats [J].
Costa, B ;
Vailati, S ;
Colleoni, M .
BEHAVIOURAL PHARMACOLOGY, 1999, 10 (03) :327-331
[8]  
COSTA B, 2000, IN PRESS PSYCHOPHARM, V149
[9]  
D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
[10]  
DAVIS LF, 1994, BIOCHEM PHARMACOL, V20, P1883